Enhancing Cancer Registries for Comparative Effectiveness Research

New Hampshire Cancer Registry

Overview
- In 2010, the Centers for Disease Control and Prevention's National Program of Cancer Registries (NPCR) funded 10 Comparative Effectiveness Research (CER) Specialized Registries.
- The NPCR funds a cancer surveillance system that collects standardized cancer incidence data for 96% of the U.S. population to support public health activities at local, state, and national levels.
- New Hampshire was selected to become a Specialized Registry for Comparative Effectiveness Research.

CDC-CER Target Questions
- Colorectal cancer
  - Are colorectal cancer patients tested for KRAS?
  - Do they receive appropriate treatment according to the results?
  - What impact does KRAS testing have on 2-3 year survival?
- Rectal cancer
  - Are patients receiving radiotherapy (RT) and what is the timing of RT?
  - Are there disparities in the appropriate neo-adjuvant use of RT?
- Chronic myeloid leukemia
  - Are CML patients being tested for the BCR-ABL2 gene
  - Do they receive appropriate treatment according to the results?
- Breast cancer
  - Are women being tested appropriately for HER2, PR2, and ER?
  - Do they receive appropriate treatment according to the results?

Purpose
- To collect a special dataset on cancer diagnosis and treatment for 2011 onwards
- To make these data (de-identified) available to researchers who complete the approval process
- To support specific research on
  - colorectal cancer
  - breast cancer
  - chronic myeloid leukemia

The Data
- A large, de-identified set of cancer registry data
  - Collected using standard methods
  - From 10 states
  - Including:
    - Patient characteristics
    - Tumor characteristics
    - Prognostic biomarkers
    - Treatment received – details of systemic treatment regimens/drugs

Summary
- These population-based, specialized cancer registry data reflect care that patients receive in all communities.
- Therefore, research using these data has the potential to impact all cancer patients.
- Participation in this project is critical to its success and to address the key CER questions.
- Researchers in New Hampshire and elsewhere can apply for permission to analyze NH and national CER data.

Questions? Contact Us
- Judy Rees, MD
  - Principal Investigator
  - 603-653-3457
  - jude.rees@dartmouth.edu
- Maria Celaya, MPH
  - Project Coordinator /data collection
  - 603-653-6621
  - maria.celaya@dartmouth.edu
- Bruce Riddle, PhD
  - Data transmission/electronic pathology laboratory reporting
  - 603-653-6620
  - bruce.riddle@dartmouth.edu
- Angeline Andrew, PhD
  - New laboratory-based prognostic biomarker surveillance/data collection
  - 603-653-9019
  - angeline.andrew@dartmouth.edu

Website: http://dms.dartmouth.edu/nhscr/